I would like to thank Karen Domino, M.D., chair of the ASAs Committee on Practice Parameters (CPP) and Girish Joshi, M.D., vice-chair of the CPP, as well as ASAs Task Force on Preoperative Fasting for their commitment to patient safety in developing this guidance. Initial reports have found that patients who have experienced GI side effects, such as nausea or vomiting, while taking GLP-1 agonists were more likely to have increased residual gastric contents
Watch for signs of severe nausea, extreme dizziness, or intense abdominal pain
Valet, M
Furthermore, the expanding investigation of semaglutide in Alzheimer's disease through the EVOKE Plus trial program, anticipated to report results by 2026 and 2027, represents a potentially enormous new indication that could add tens of millions of patients to the addressable treatment population globally, with corresponding API volume requirements that dwarf those of the existing obesity and diabetes indications
doi:10.1038/npjamd.2016.3 33